<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>PILMAN &#187; plus</title>
	<atom:link href="http://www.tapanray.in/tag/plus/feed/" rel="self" type="application/rss+xml" />
	<link>http://www.tapanray.in</link>
	<description>A Tapan Ray Website</description>
	<lastBuildDate>Sun, 22 Mar 2026 10:59:18 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>hourly</sy:updatePeriod>
	<sy:updateFrequency>1</sy:updateFrequency>
	<generator>http://wordpress.org/?v=3.4.2</generator>
		<item>
		<title>‘Data Protection’: Needs A Clear Direction…But Is It An IPR Issue?</title>
		<link>http://www.tapanray.in/data-protection-needs-a-clear-directionbut-is-it-an-ipr-issue/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=data-protection-needs-a-clear-directionbut-is-it-an-ipr-issue</link>
		<comments>http://www.tapanray.in/data-protection-needs-a-clear-directionbut-is-it-an-ipr-issue/#comments</comments>
		<pubDate>Mon, 02 Mar 2015 00:00:51 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[39.3]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Charles]]></category>
		<category><![CDATA[CL]]></category>
		<category><![CDATA[Clift]]></category>
		<category><![CDATA[Committee]]></category>
		<category><![CDATA[cosmetics]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[Drug]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[issue]]></category>
		<category><![CDATA[National]]></category>
		<category><![CDATA[NCE]]></category>
		<category><![CDATA[Patents]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[plus]]></category>
		<category><![CDATA[Policy]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Reddy]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Satwant]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Tapan Ray]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[WTO]]></category>

		<guid isPermaLink="false">http://www.tapanray.in/?p=6397</guid>
		<description><![CDATA[The terminologies ‘Data Exclusivity’ and ‘Data Protection’ are quite often used interchangeably by many, creating a great deal of confusion on the subject. However, in a true sense these are quite different issues having critical impact on public health interest &#8230; <a href="http://www.tapanray.in/data-protection-needs-a-clear-directionbut-is-it-an-ipr-issue/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/data-protection-needs-a-clear-directionbut-is-it-an-ipr-issue/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>The Game Changer: Effective transition from ‘blockbuster’ to an integrated ‘niche buster’ plus &#8216;generic drugs&#8217; business model</title>
		<link>http://www.tapanray.in/the-game-changer-effective-transition-from-blockbuster-to-an-integrated-niche-buster-plus-generic-drugs-business-model/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=the-game-changer-effective-transition-from-blockbuster-to-an-integrated-niche-buster-plus-generic-drugs-business-model</link>
		<comments>http://www.tapanray.in/the-game-changer-effective-transition-from-blockbuster-to-an-integrated-niche-buster-plus-generic-drugs-business-model/#comments</comments>
		<pubDate>Sun, 20 Nov 2011 07:58:47 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[an]]></category>
		<category><![CDATA[blockbuster]]></category>
		<category><![CDATA[buster]]></category>
		<category><![CDATA[Changer]]></category>
		<category><![CDATA[drugs. business]]></category>
		<category><![CDATA[effective]]></category>
		<category><![CDATA[From]]></category>
		<category><![CDATA[Game]]></category>
		<category><![CDATA[generic]]></category>
		<category><![CDATA[integrated]]></category>
		<category><![CDATA[model]]></category>
		<category><![CDATA[niche]]></category>
		<category><![CDATA[pharmaceutical]]></category>
		<category><![CDATA[plus]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[to]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=172</guid>
		<description><![CDATA[Since quite some time global pharmaceutical majors have been operating within the confines of high risk &#8211; high reward R&#38;D based business model with blockbuster drugs (annual sales of over US$ 1 billion). Blockbuster brands, mostly in the chronic-care segments &#8230; <a href="http://www.tapanray.in/the-game-changer-effective-transition-from-blockbuster-to-an-integrated-niche-buster-plus-generic-drugs-business-model/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/the-game-changer-effective-transition-from-blockbuster-to-an-integrated-niche-buster-plus-generic-drugs-business-model/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
		<item>
		<title>EU-FTA, TRIPS-Plus provisions, Data Exclusivity, Public Interest and India</title>
		<link>http://www.tapanray.in/eu-fta-trips-plus-provisions-data-exclusivity-public-interest-and-india/?utm_source=rss&#038;utm_medium=rss&#038;utm_campaign=eu-fta-trips-plus-provisions-data-exclusivity-public-interest-and-india</link>
		<comments>http://www.tapanray.in/eu-fta-trips-plus-provisions-data-exclusivity-public-interest-and-india/#comments</comments>
		<pubDate>Sun, 30 Jan 2011 11:00:29 +0000</pubDate>
		<dc:creator>Tapan Ray</dc:creator>
				<category><![CDATA[Pharma]]></category>
		<category><![CDATA[&]]></category>
		<category><![CDATA[Act]]></category>
		<category><![CDATA[Affordability]]></category>
		<category><![CDATA[agreement]]></category>
		<category><![CDATA[amendment]]></category>
		<category><![CDATA[cosmetics]]></category>
		<category><![CDATA[data]]></category>
		<category><![CDATA[drugs]]></category>
		<category><![CDATA[EU]]></category>
		<category><![CDATA[EUFTA]]></category>
		<category><![CDATA[European]]></category>
		<category><![CDATA[Exclusivity]]></category>
		<category><![CDATA[Free]]></category>
		<category><![CDATA[FTA]]></category>
		<category><![CDATA[India]]></category>
		<category><![CDATA[Interest. and]]></category>
		<category><![CDATA[IP]]></category>
		<category><![CDATA[IPR]]></category>
		<category><![CDATA[NCE]]></category>
		<category><![CDATA[NME]]></category>
		<category><![CDATA[of]]></category>
		<category><![CDATA[Patent]]></category>
		<category><![CDATA[plus]]></category>
		<category><![CDATA[Protection]]></category>
		<category><![CDATA[Provisions]]></category>
		<category><![CDATA[public]]></category>
		<category><![CDATA[Ray]]></category>
		<category><![CDATA[regulations]]></category>
		<category><![CDATA[Regulatory]]></category>
		<category><![CDATA[Tapan]]></category>
		<category><![CDATA[Trade]]></category>
		<category><![CDATA[TRIPS]]></category>
		<category><![CDATA[Union]]></category>

		<guid isPermaLink="false">http://tapanray.in/index.php/?p=308</guid>
		<description><![CDATA[Business Standard in its January 27, 2011 edition reported, “Data Exclusivity still key hurdle to India-EU FTA” Before deliberating on this important issue of “Free Trade Agreement (FTA)”, let me touch upon very briefly, for the benefit of all concerned, &#8230; <a href="http://www.tapanray.in/eu-fta-trips-plus-provisions-data-exclusivity-public-interest-and-india/">Continue reading <span class="meta-nav">&#8594;</span></a>]]></description>
		<wfw:commentRss>http://www.tapanray.in/eu-fta-trips-plus-provisions-data-exclusivity-public-interest-and-india/feed/</wfw:commentRss>
		<slash:comments>0</slash:comments>
		</item>
	</channel>
</rss>
